Professor, Internal Medicine, UCSF School of Medicine
Allergy & Immunology
Dr. Daniel S. Adelman, DDS
|
|
Give Review
Daniel Adelman is an expert in the field of Allergy & Immunology. He attended University of California Davis School of Medicine. University of California Davis School of Medicine is ranked 43 in research and 19 in primary care medicine He received 3 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification" and "Fellow (FAAAAI)". Daniel Adelman is a published MD. He has 26 publications published. The most current publication "Clinical differences among women with and without self-reported perimenstrual asthma."
Publications
- Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials.
- Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
- Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
- A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in p...
- Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing perc...
- Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
- Pharmacological approaches.
- A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
- Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advance...
- Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
- Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin).
- Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
- 13-cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency.
- The cross-reactivity and immunology of beta-lactam antibiotics.
- Clinical differences among women with and without self-reported perimenstrual asthma.
- Letter to the editor regarding the use of intravenous immunoglobulin (IVIG) in asthma.
- Neuroimmunology.
- Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects.
- Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency.
- Neuropeptides, mast cells and allergy: novel mechanisms and therapeutic possibilities.
- Fixed cutaneous eruptions to seminal-plasma challenge: a case report.
- Molecular characteristics of the cellular receptor for vasoactive intestinal peptide.
- Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide.
- Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
- Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Doctors Specialties
- Dentistry
- Allergy
- Immunology
Accepted Insurances
- Dental DPPO
- Ameritas PPO
- DHA
- DHA Premier
- Dental PPO
- CompBenefits Corp. PPO
- Delta Dental PPO
- Delta Dental Premier
- Dental Network of America DPPO
- DenteMax
- DentalGuard Preferred
- Humana PPO
- MetLife PDP
- Advantage Plus PPO
- National Fee-for-Service
- Dental
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Fellow (FAAAAI)
Education
-
Cedars-Sinai Medical Center -
University of California Davis School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
Alta Bates Summit Medical Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1922041821 | |
| NPPES Provider LastName | ADELMAN | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 941432202 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 57.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922041821 |
| Last Name Of The Provider | ADELMAN |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
Dr. James A. Nickelsen, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Nataliya M. Kushnir, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sixto F. Guiang Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter E. Freedman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Gianni, DDS |
|
|
Dr. Farnaz Shadravan, DDS |
|
|
Dr. Amy K. Lee, DDS |
|
|
Dr. Whitney R. Johnson, DDS |
|
|
Dr. Jung S. Park, DDS |